Purple Biotech (PPBT) Net Cash Flow (2017 - 2026)
Purple Biotech (PPBT) reported Net Cash Flow of -$3.1 million for Q1 2026, down 94.07% year-over-year from -$52.9 million in Q1 2025, and down 259.27% quarter-over-quarter from -$874000.0 in Q4 2025.
Purple Biotech (PPBT) Net Cash Flow (2017 - 2026) Analysis & Trends
Purple Biotech (PPBT) has 10 years of Net Cash Flow data on file, last reported at -$3.1 million in Q1 2026.
- Net Cash Flow for Q1 2026 came in at -$3.1 million, down 94.07% year-over-year; the trailing twelve-month figure through Mar 2026 was -$213000.0 (up 94.93% YoY), and the FY2025 annual result was $1.3 million, up 118.48% from the prior year.
- Net Cash Flow retreated to -$3.1 million in Q1 2026 per PPBT's latest filing, from -$874000.0 in the prior quarter.
- Over five years, Net Cash Flow peaked at $12.7 million in Q1 2022 and troughed at -$9.4 million in Q2 2022.
- A 5-year average of -$306882.4 and a median of -$1.1 million in 2024 frame the typical range for Net Cash Flow.
- On a YoY basis, Net Cash Flow climbed as much as 1565.66% in 2022 and fell as far as 3228.0% in 2022.
- A 5-year view of Net Cash Flow shows it stood at $3.9 million in 2022, then tumbled by 117.09% to -$662000.0 in 2023, then jumped by 396.53% to $2.0 million in 2024, then tumbled by 144.52% to -$874000.0 in 2025, then sank by 259.27% to -$3.1 million in 2026.
- Business Quant data shows PPBT's Net Cash Flow at -$3.1 million in Q1 2026, -$874000.0 in Q4 2025, and $4.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 625.70 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -2.44 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 457.40 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 664,983.53 |
| 10 | Purple Biotech | 242.86 Mn | 236.43 Mn | - | -3.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.14 Mn |
| Mar 31, 2026 | -3.14 Mn |
| Dec 31, 2025 | -874,000.00 |
| Dec 31, 2025 | -874,000.00 |
| Sep 30, 2025 | 4.87 Mn |
| Sep 30, 2025 | 4.87 Mn |
| Jun 30, 2025 | -1.07 Mn |
| Jun 30, 2025 | -1.07 Mn |
| Mar 31, 2025 | -1.62 Mn |
| Mar 31, 2025 | -1.62 Mn |
| Dec 31, 2024 | 1.96 Mn |
| Dec 31, 2024 | 1.96 Mn |
| Sep 30, 2024 | -1.09 Mn |
| Sep 30, 2024 | -1.09 Mn |
| Jun 30, 2024 | -3.46 Mn |
| Jun 30, 2024 | -3.46 Mn |
| Mar 31, 2024 | -4.50 Mn |
| Mar 31, 2024 | -4.50 Mn |
| Dec 31, 2023 | -662,000.00 |
| Dec 31, 2023 | -662,000.00 |